Roche CEO: Future of cancer treatment, AI in Medicine and Trial Challenges

What’s next for cancer treatment and personalized medicine? How is AI reshaping the future of drug discovery? And can Europe keep pace with China’s rapid rise in health care innovation? In this episode, Nicolai welcomes Thomas Schinecker, CEO of Roche, one of the world’s largest health care companies. They discuss Roche’s leadership in cancer treatment, breakthroughs in diagnostics, and the impact of cutting-edge R&D in areas like precision medicine and AI. Schinecker also shares his views on the rapid growth of China’s pharma industry and the challenges Europe faces in keeping up with global clinical trials.

The production team for this episode includes Isabelle Karlsson and PLAN-B's Niklas Figenschau Johansen, Sebastian Langvik-Hansen and Pål Huuse. Background research was conducted by Sara Arnesen.

• Watch the episode on YouTube: Norges Bank Investment Management - YouTube
• Want to learn more about the fund? The fund | Norges Bank Investment Management (nbim.no)
• Follow Nicolai Tangen on LinkedIn: Nicolai Tangen | LinkedIn
• Follow NBIM on LinkedIn: Norges Bank Investment Management: Administrator for bedriftsside | LinkedIn
• Follow NBIM on Instagram: Explore Norges Bank Investment Management on Instagram

Hosted on Acast. See acast.com/privacy for more information.

What’s next for cancer treatment and personalized medicine? How is AI reshaping the future of drug discovery? And can Europe keep pace with China’s rapid rise in health care innovation? In this episode, Nicolai welcomes Thomas Schinecker, CEO of Roche, one of the world’s largest health care companies. They discuss Roche’s leadership in cancer treatment, breakthroughs in diagnostics, and the impact of cutting-edge R&D in areas like precision medicine and AI. Schinecker also shares his views on the rapid growth of China’s pharma industry and the challenges Europe faces in keeping up with global clinical trials.

The production team for this episode includes Isabelle Karlsson and PLAN-B's Niklas Figenschau Johansen, Sebastian Langvik-Hansen and Pål Huuse. Background research was conducted by Sara Arnesen.

• Watch the episode on YouTube: Norges Bank Investment Management - YouTube
• Want to learn more about the fund? The fund | Norges Bank Investment Management (nbim.no)
• Follow Nicolai Tangen on LinkedIn: Nicolai Tangen | LinkedIn
• Follow NBIM on LinkedIn: Norges Bank Investment Management: Administrator for bedriftsside | LinkedIn
• Follow NBIM on Instagram: Explore Norges Bank Investment Management on Instagram

Hosted on Acast. See acast.com/privacy for more information.

We've curated a special 10-minute version of the podcast for those in a hurry.

Here you can listen to the full episode: https://podcasts.apple.com/no/podcast/apollo-ceo-private-markets-investment-alpha-and-risk/id1614211565?i=1000676757534&l=nb

What does it take to stay resilient in a fast-changing financial world? How are private markets transforming the way we invest? And how does Apollo approach risk? Nicolai Tangen meets with Marc Rowan, CEO and co-founder of Apollo Global Management, to discuss the rapidly evolving world of finance and explore what it takes to stay ahead in an industry full of risks.

In Good Company is hosted by Nicolai Tangen, CEO of Norges Bank Investment Management. New full episode out every Wednesday, and don't miss our Highlight episodes every Friday.

The production team for this episode includes Isabelle Karlsson and PLAN-B’s Niklas Figenschau Johansen, Sebastian Langvik-Hansen and Pål Huuse, with research by Isabelle Karlsson.

• Watch the episode on YouTube: Norges Bank Investment Management - YouTube
• Want to learn more about the fund? The fund | Norges Bank Investment Management (nbim.no)
• Follow Nicolai Tangen on LinkedIn: Nicolai Tangen | LinkedIn
• Follow NBIM on LinkedIn: Norges Bank Investment Management: Administrator for bedriftsside | LinkedIn
• Follow NBIM on Instagram: Explore Norges Bank Investment Management on Instagram

Hosted on Acast. See acast.com/privacy for more information.